Cargando…
Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer
BACKGROUND: Advances in cancer immunotherapy have generated encouraging results in multiple malignancies refractory to standard chemotherapies. As the use of immune checkpoint inhibitors (ICI) proliferates, the incidence of autoimmune side effects associated with these agents, termed immune related...
Autores principales: | Godwin, James Luke, Jaggi, Shuchie, Sirisena, Imali, Sharda, Pankaj, Rao, Ajay D., Mehra, Ranee, Veloski, Colleen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433051/ https://www.ncbi.nlm.nih.gov/pubmed/28515940 http://dx.doi.org/10.1186/s40425-017-0245-2 |
Ejemplares similares
-
Development of autoimmune diabetes with severe diabetic ketoacidosis and immune-related thyroiditis secondary to durvalumab: a case report
por: Lopes, Ana Rita, et al.
Publicado: (2020) -
SUN-173 Nivolumab-Induced Fulminant Autoimmune Diabetes Presenting as Diabetic Ketoacidosis in a Patient with Melanoma
por: Parikh, Sahil, et al.
Publicado: (2019) -
Nivolumab-induced fulminant diabetic ketoacidosis followed by thyroiditis
por: Tzoulis, Ploutarchos, et al.
Publicado: (2018) -
Rapid-onset diabetic ketoacidosis secondary to nivolumab therapy
por: Lee, Senhong, et al.
Publicado: (2018) -
SUN-LB036 Diabetic Ketoacidosis: A Rare Side Effect of Nivolumab Induced Insulin Dependent Diabetes Mellitus
por: Abid, Haisam, et al.
Publicado: (2019)